Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion And Bayer Hope Novel Drugs Can Take Over The Pulmonary Hypertension Market

Executive Summary

Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.

Advertisement

Related Content

FDA Review Of Bayer’s Riociguat Suggests It’s All About The Dose
U.S./EU Filings Position Bayer Compound As First Approval For CTEPH
U.S./EU Filings Position Bayer Compound As First Approval For CTEPH
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
Viagra’s End Begins: Generic Sildenafil Launches For Revatio
Street Unsurprised By CRL For Oral Treprostinil, But United Therapeutics’ Stock Tumbles Anyway
Actelion CEO Seeks To Rebuild Investor Confidence As Pressure Builds On Tracleer
PAH’s Two Main Players Edging Toward Head-To-Head Competition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel